Oregon Public Employees Retirement Fund I Teos Therapeutics, Inc. Transaction History

Oregon Public Employees Retirement Fund

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 26, 2023	BUY	$10.95 - $14.6 $2,190 - $2,920	200 Added 2.59%	7,915 $86,000
Q2 2023 Jul 26, 2023	SELL	$12.93 - $18.05 $5,172 - $7,220	-400 Reduced 4.93%	7,715 $102,000
Q1 2023 May 04, 2023	SELL	$13.02 - $22.62 $260 - $452	-20 Reduced 0.25%	8,115 $110,000
Q4 2022 Jan 26, 2023	SELL	$17.77 - $21.6 $248 - $302	-14 Reduced 0.17%	8,135 $0
Q3 2022 Nov 01, 2022	BUY	$18.6 - $27.25 $27,900 - $40,875	1,500 Added 22.56%	8,149 $155,000
Q2 2022 Jul 25, 2022	SELL	$16.57 - $35.1 $14,913 - $31,590	-900 Reduced 11.92%	6,649 $137,000
Q1 2022 Apr 21, 2022	BUY	$31.92 - $47.45 $240,964 - $358,200	7,549 New	7,549 $243,000

166

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $257M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Oregon Public Employees Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on Oregon Public Employees Retirement Fund with notifications on news.